



Menopause

The Journal of The North American Menopause Society

VOLUME 26, ISSUE 8 2019

SDC

Supplemental Digital Content is available.

CONTENTS

Editorials

809

Sexual pain in the menopausal patient: individualizing treatment still best

Gloria Bachmann, MD

811

Understanding the unmet sexual health needs of women with breast cancer

Stephanie S. Faubion, MD, and Sheryl A. Kingsberg, PhD

814

Vaginal laser treatment—first, do no harm

Martha Hickey, BA (Hons), MSc, MBChB, FRCOG, FRANZCOG, MD, and Anthony M. Richards, MBBS, MRMed, MBA, RANZCOG, CGO

Original Articles

816

Sexual frequency and pain in a randomized clinical trial of vaginal estradiol tablets, moisturizer, and placebo in postmenopausal women

Caroline M. Mitchell, MD, MPH, Katherine A. Guthrie, PhD, Joseph Larson, MS, Susan Diem, MD, Andrea Z. LaCroix, PhD, Bette Caan, DrPH, Jan L. Shifren, MD, Nancy F. Woods, PhD, RN, Julia R. Heiman, PhD, Stacy T. Lindau, MD, MAPP, and Susan D. Reed, MD, MPH

In a randomized, 12-week trial of vaginal estradiol or vaginal moisturizer vs dual placebo for treatment of moderate-severe vulvovaginal discomfort, no difference was found between arms in engagement in or frequency of sexual activity, nor in pain scores with sex.

(continued)

Menopause: The Journal of The North American Menopause Society (ISSN 1072-3714) is published monthly for The North American Menopause Society by Wolters Kluwer Health, Inc. Business and production offices are located at Two Commerce Square, 2001 Market St., Philadelphia, PA 19103. All rights reserved. Copyright © 2019 by The North American Menopause Society.

POSTMASTER: Send address changes to *Menopause: The Journal of The North American Menopause Society*, P.O. Box 1610, Hagerstown, MD 21740.

823

Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy

Caroline S. Dorfman, PhD, Sarah S. Arthur, MA, Gretchen G. Kimmick, MD, Kelly W. Westbrook, MD, Paul Kelly Marcom, MD, Cheyenne Corbett, PhD, Sara N. Edmond, PhD, and Rebecca A. Shelby, PhD

The present study found greater sexual problems and lower sexual self-efficacy to be associated with poorer psychosocial quality-of-life and sexual satisfaction among postmenopausal breast cancer survivors taking adjuvant endocrine therapy.

833

Fractional CO₂ laser versus promestriene and lubricant in genitourinary syndrome of menopause: a randomized clinical trial

Carlos A. Politano, MD, Lucia Costa-Paiva, MD, PhD, Luiza B. Aguiar, MD, Helymar C. Machado, MSc, and Luiz F. Baccaro, MD, PhD

Fractional CO₂ laser therapy as a treatment for genitourinary syndrome showed better short-term effects than promestriene and lubricant in improving vaginal health in postmenopausal women.

841

Women's Health Initiative clinical trials: potential interactive effect of calcium and vitamin D supplementation with hormonal therapy on cardiovascular disease

Xuezhi Jiang, MD, PhD, Matthew Nudy, MD, Aaron K. Aragaki, MS, John A. Robbins, MD, JoAnn E. Manson, MD, DrPH, Marcia L. Stefanick, PhD, David M. O'Sullivan, PhD, James M. Shikany, DrPH, Erin S. LeBlanc, MD, MPH, Anita M. Kelsey, MD, Jane Cauley, DrPH, Lisa W. Martin, MD, Martha E. Payne, PhD, RD, MPH, Karen C. Johnson, MD, MPH, Barbara Howard, PhD, and Peter F. Schnatz, DO, FACP, FACOG, NCMP

Calcium and vitamin D supplementation did not consistently modify the effect of hormone therapy on cardiovascular disease events. Calcium and vitamin D supplementation did, however, appear to mitigate the risk of stroke from CEE therapy.

850

Confirmatory factor analysis of the Insomnia Severity Index (ISI) and invariance across race: a pooled analysis of MsFLASH data

Julie L. Otte, PhD, RN, Giorgos Bakoyannis, PhD, Kevin L. Rand, PhD, Kristine E. Ensrud, MD, MPH, Katherine A. Guthrie, PhD, Hadine Joffe, MD, MSc, Susan M. McCurry, PhD, Kathrine M. Newton, PhD, and Janet S. Carpenter, PhD, RN, FAAN

The Insomnia Severity Index in midlife women with hot flashes is composed of two factors that capture dimensions of the insomnia severity and daytime impact. The instrument is a psychometrically sound scale appropriate for use in research and clinical practice to capture the severity and daytime impact of insomnia symptoms in diverse samples of midlife women with hot flashes.

856

Accuracy of the Menopause Rating Scale and the Menopause Quality of Life Questionnaire to discriminate menopausal women with anxiety and depression

Carolina Marín Martín, PhD, Cristina Larroy, PhD, Amanda López-Picado, PhD, and Ignacio Fernández-Arias, PhD

The MRS and MENQOL display moderate accuracy in detecting menopausal women with symptoms of anxiety and depression. The intensity of the symptoms appears to be related to the probability of detecting a probable or definitive disorder.

863

Tamoxifen use as a malignancy risk factor in postmenopausal women with endometrial polyps

Daniela Angerame Yela, MD, PhD, Thales Akio Ikejiri, MD, Carolina Ribeiro Machado, MD, Danielle Mutta, MD, and Cristina Laguna Benetti-Pinto, MD, PhD

Tamoxifen use was not related to a higher prevalence of endometrial cancer in women with endometrial polyps. Abnormal uterine bleeding, age > 60 years, and nulliparous status were associated with malignancy.

867

The effect of a randomized 12-week soy drink intervention on everyday mood in postmenopausal women

Ellen E.A. Simpson, PhD, Orlaith N. Furlong, Heather J. Parr, PhD, Stephanie J. Hodge, PhD, Mary M. Slevin, PhD, Emeir M. McSorley, PhD, Jacqueline M. McCormack, PhD, Christopher McConville, PhD, and Pamela J. Magee, PhD

Soy isoflavones had no effect on mood at any of the doses tested. Future research should focus on the menopausal transition from peri- to postmenopause as there may be a window of vulnerability, with fluctuating hormones and increased symptoms which may affect mood.

SDC

874

Safety and feasibility of estrogen receptor- β targeted phytoSERM formulation for menopausal symptoms: phase 1b/2a randomized clinical trial

Lon S. Schneider, MD, MS, Gerson Hernandez, MD, MPH, Liqin Zhao, PhD, Adrian A. Franke, PhD, Yu-Ling Chen, MS, Sonia Pawluczyk, MD, Wendy J. Mack, PhD, and Roberta D. Brinton, PhD

The phytoSERM formulation was well-tolerated at 50 and 100 mg daily doses. Based on safety outcomes, vaginal bleeding at the 100 mg dose, and vasomotor symptoms and cognitive outcomes at 12 weeks at a daily dose of 50mg was considered preferable for a phase 2 efficacy trial.

SDC

885

Life-long endogenous estrogen exposure is associated with prevalence of allergic rhinitis in postmenopausal women

Kijeong Lee, MD, Yeji Hong, BS, Jimi Choi, MS, Sang Hag Lee, MD, PhD, and Tae Hoon Kim, MD, PhD

Longer duration of reproductive periods was associated with higher prevalence of allergic rhinitis and aeroallergen sensitization in the postmenopausal period.

892

Hormone therapy is not associated with the risk of sudden sensorineural hearing loss in postmenopausal women: a 10-year nationwide population-based study

Po-Jun Chen, MD, Chi-Hsiang Chung, PhD, Wu-Chien Chien, PhD, and Hsin-Chien Chen, MD, PhD

This study demonstrated that hormone therapy (HT) did not increase the risk of sudden sensorineural hearing loss (SSNHL) in menopausal women. Thus, SSNHL may not be a risk that should be considered when evaluating the use of HT in postmenopausal women.

SDC

899

Effects of 8 weeks of moderate-intensity resistance training on muscle changes in postmenopausal women with different angiotensin-converting enzyme insertion/deletion polymorphisms of interest

Lingxiao He, MS, Xinming Zhang, MS, Yuanyuan Lv, PhD, Boya Gu, MS, and Li Zhao, PhD

This study explored the association between the ACE I/D polymorphism and muscle adaptations to a moderate-intensity resistance training program in postmenopausal women. Women with the ACE DD genotype had predominant adaptations in grip strength, cross-sectional area of rectus femoris, and knee extensor strength.

906

Cost-effectiveness of antiosteoporosis strategies for postmenopausal women with osteoporosis in China

Na Li, MS, Bin Zheng, PhD, Maobai Liu, MS, Haimei Zhou, MD, Lingfen Zhao, MD, Hongfu Cai, MS, and Jingze Huang, MS

This study estimated the cost-effectiveness of alendronate, zoledronate, raloxifene, teriparatide, and calcium/vitamin D strategies for the treatment of osteoporosis in elderly postmenopausal women in China from the medical system perspective. Zoledronate is likely to be more cost-effective.

Case Report

915

Reversible alopecia associated with high blood mercury levels and early menopause: a report of two cases

Jane B. Peters, BA, and Michelle P. Warren, MD

Two women with early menopause complained of hair loss and both were found to have high mercury levels. A decrease in mercury levels led to regrowth of hair.

Review Articles

919

An individualized approach to the management of vaginal atrophy in Latin America

Santiago Palacios, MD, PhD, Rossella E. Nappi, MD, PhD,

Marla Shapiro, CM, MDCM, CCFP, MHSc, FRCPC, FCFP, NCMP,

Nilson Roberto de Melo, MD, PhD, María Celeste Osorio Wender, MD, PhD,

César Eduardo Fernandes, MD, PhD, Dolores Pardini, MD, PhD,

Rogério Bonassi Machado, MD, PhD, Jaime Kulak Jr, MD, PhD,

Cuauhtémoc Celis-González, MD, Mabel T. Martino, MD, Rita R. Pizzi, MD,

Paulina Villaseca, MD, Eduardo Storch, MD, Luis Fernando Danckers, MD, and

José Alberto Hernández-Bueno, MD

Educating women and healthcare providers to engage in open dialogue will facilitate appreciation of the benefits and means of maintaining urogenital health, helping to improve outcomes in middle-age and beyond. Women should receive this education prior to menopause.

CONTENTS

(continued)

SDC

929

Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China)

Xiang Tan, BS, Fei Wen, MS, Wei Yang, MS, Ji-Yong Xie, BS, Liang-Liang Ding, MS, and Yu-Xia Mo, MS

The aim of this study was to assess the comparative effectiveness and safety of different pharmacological agents including abaloparatide and romosozumab, neither of which have been mentioned in the American College of Physicians Guideline Update of 2017, for osteoporosis in postmenopausal women.

Letters to the Editor

940

Wolters Kluwer Health, Inc., and The North American Menopause Society cannot be held responsible for errors or for any consequences arising from the use of the information contained in this journal. All advertising material published in this journal is expected to conform to regulatory and medical standards. The appearance of advertising in this publication does not constitute a guarantee or endorsement by The North American Menopause Society or Wolters Kluwer Health, Inc., of the quality or value of such a product or service or any claims made by its marketer.

Permissions and photocopying: For permission and/or rights to use content for which the copyright holder is Wolters Kluwer or the society we have partnered with the Copyright Clearance Center to provide permissions for our products through their RightsLink service, please go to the journal's website and after clicking on the relevant article, click on the "Get Content & Permissions" link under the "Article Tools" box that appears on the right side of the page. For questions about the Rightslink service, e-mail customer care@copyright.com or call 877-622-5543 (U.S. Only) or 978-777-9929. Permissions FAQs and information on author's permission requests are available at <https://shop.lww.com/journal-permission>. For additional permission inquiries, please contact Permissions@LWW.com. For translation rights requests, contact TranslationRights@wolterskluwer.com. For license to republish and distribute requests, contact HealthLicensing@wolterskluwer.com. For special projects and reprints (U.S./Canada), contact Alan Moore at Alan.Moore@wolterskluwer.com or reprintsolutions@wolterskluwer.com. For special projects and reprints (non-U.S./Canada), contact Avia Potashnik at Avia.Potashnik@wolterskluwer.com or International-Reprints@wolterskluwer.com.

Menopause: The Journal of The North American Menopause Society is a registered trademark of The North American Menopause Society.

Menopause: The Journal of The North American Menopause Society (ISSN 1072-3714) is published monthly by Wolters Kluwer Health, Inc., at 14700 Citicorp Drive, Bldg 3, Hagerstown, MD 21742. Business offices are located at Two Commerce Square, 2001 Market St., Philadelphia, PA 19103. **Annual subscription rate:** \$581.

Copyright © 2019 by The North American Menopause Society. All rights reserved. Printed in the USA.